Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
Sponsor: BioCryst Pharmaceuticals
Summary
The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.
Official title: An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects With Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
2
Start Date
2022-02-18
Completion Date
2022-09-23
Last Updated
2026-11-10
Healthy Volunteers
No
Interventions
BCX9930
Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
Locations (11)
Investigative Site
Poitiers, France
Investigative Site
Toulouse, France
Investigative Site
Bari, Italy
Investigative Site
Bergamo, Italy
Investigative Site
Brescia, Italy
Investigative Site
Turin, Italy
Investigative Site #1
Barcelona, Spain
Investigative Site #2
Barcelona, Spain
Investigative Site #1
Madrid, Spain
Investigative Site #2
Madrid, Spain
Investigative Site
Oxford, United Kingdom